Rechercher un essai clinique
Autre(s) option(s) de recherche
107 Résultat(s)
Essai en cours de recrutement = 
; Essai en cours = 
; Essai terminé = 
; Financé par un membre IRDiRC = 
; Membre d'un ERN = 
Essai(s) clinique(s) national(aux)
ALLEMAGNE
Baden-Württemberg
FREIBURG
A phase III, multicenter, randomized, double-blind, placebo-controlled study of atezolizumab (anti-PD-L1 antibody) as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck -DE-
Universitätsklinikum Freiburg
Klinik für Strahlenheilkunde
ALLEMAGNE
Baden-Württemberg
HEIDELBERG
NOA-20/Improvement of functional outcome for patients with newly diagnosed grade II or III glioma with co-deletion of 1p/19q - IMPROVE CODEL
Neurologische Universitätsklinik Heidelberg
Abteilung für Neuroonkologie
ALLEMAGNE
Baden-Württemberg
HEIDELBERG
TREASURE: Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease: a Randomized, Open-label, Multicenter Phase II Study - DE
Thoraxklinik-Heidelberg gGmbH
Thoraxklinik Heidelberg
ALLEMAGNE
Baden-Württemberg
HEIDELBERG
CUPISCO: A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy -DE
Zentrum für Innere Medizin (Krehl-Klinik)
Medizinische Klinik V - Hämatologie, Onkologie und Rheumatologie
ALLEMAGNE
Baden-Württemberg
MANNHEIM
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - DE
Universitätsmedizin Mannheim
III. Medizinische Klinik
ALLEMAGNE
Baden-Württemberg
TÜBINGEN
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - DE
Department für Innere Medizin - Medizinische Universitätsklinik Tübingen
Innere Medizin I - Gastroenterologie, Hepatologie und Infektiologie
ALLEMAGNE
Baden-Württemberg
ULM
CONTACT-03: A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment -DE
Universitätsklinikum Ulm am Michelsberg
Klinik für Kinderurologie
ALLEMAGNE
Bayern
MÜNCHEN
A phase III, multicenter, randomized, double-blind, placebo-controlled study of atezolizumab (anti-PD-L1 antibody) as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck -DE-
Klinikum rechts der Isar der Technischen Universität München
Klinik und Poliklinik für RadioOnkologie und Strahlentherapie
ALLEMAGNE
Bayern
MÜNCHEN
DEMAND: A randomized, 2-arm non-comparative phase II study on the efficacy of atezolizumab and Roche bevacizumab (Atezo/Bev) followed by on-demand selective TACE (sdTACE) upon detection of disease progression or of initial synchronous treatment with TACE and Atezo/Bev on 24-months survival rate in the treatment of unresectable HCC patients
LMU Klinikum der Universität München - Campus Großhadern
Medizinische Klinik und Poliklinik II
ALLEMAGNE
Bayern
REGENSBURG
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - DE
Universitätsklinikum Regensburg
Klinik und Poliklinik für Strahlentherapie
ALLEMAGNE
Berlin
ADDRESS: NOT PROVIDED - DE
AGO-OVAR 2.29: Atezolizumab in Combination With Bevacizumab and Chemotherapy Versus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer - a Randomized Phase III Trial - DE
Institution: Information not provided - DE
ALLEMAGNE
Berlin
ADDRESS: NOT PROVIDED - DE
A phase II, randomized study of MPDL3280A administered as monotherapy or in combination with Bevacizumab versus Sunitinib in patients with untreated advanced renal cell carcinoma - DE
Institution: Information not provided - DE
ALLEMAGNE
Berlin
ADDRESS: NOT PROVIDED - DE
A Phase Ib/II Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without - DE
Institution: Information not provided - DE
ALLEMAGNE
Berlin
BERLIN
A phase III, multicenter, randomized, double-blind, placebo-controlled study of atezolizumab (anti-PD-L1 antibody) as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck -DE-
Charité - Universitätsmedizin Berlin (CBF)
Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie (CBF)
ALLEMAGNE
Hamburg
HAMBURG
CONTACT-03: A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment -DE
UKE - Universitätsklinikum Hamburg-Eppendorf
Klinik und Poliklinik für Urologie
ALLEMAGNE
Hessen
FRANKFURT AM MAIN
CONTACT-03: A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment -DE
Universitätsklinikum Frankfurt
KiRaFe Studienleitung - Klinik für Kinderchirurgie und Kinderurologie
ALLEMAGNE
Hessen
MARBURG
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - DE
Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg
UKGM - Universitätsklinikum Gießen und Marburg GmbH
ALLEMAGNE
Niedersachsen
GÖTTINGEN
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - DE
Universitätsmedizin Göttingen
Klinik für Gastroenterologie, gastrointestinale Onkologie und Endokrinologie
ALLEMAGNE
Nordrhein-Westfalen
BONN
A phase III, multicenter, randomized, double-blind, placebo-controlled study of atezolizumab (anti-PD-L1 antibody) as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck -DE-
Universitätsklinikum Bonn (AöR)
Medizinische Klinik und Poliklinik III - Innere Medizin (Onkologie, Hämatologie, Immunonkologie und Rheumatologie)
ALLEMAGNE
Nordrhein-Westfalen
DÜSSELDORF
ATALANTE : A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab -DE-
Universitätsklinikum Düsseldorf
Frauenklinik
ALLEMAGNE
Nordrhein-Westfalen
ESSEN
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - DE
Evang. Kliniken Essen-Mitte gGmbH
ALLEMAGNE
Nordrhein-Westfalen
ESSEN
BOUQUET: A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors -DE
Evang. Kliniken Essen-Mitte gGmbH
Klinik für Gynäkologie & Gynäkologischer Onkologie
ALLEMAGNE
Nordrhein-Westfalen
ESSEN
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - DE
Universitätsklinikum Essen
Klinik für Strahlentherapie
ALLEMAGNE
Rheinland-Pfalz
MAINZ
The ABC-HCC Trial: A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoembolization (TACE) in intermediate-stage Hepatocellular carcinoma -DE
Universitätsmedizin Mainz
I. Medizinische Klinik und Poliklinik
ALLEMAGNE
Sachsen
DRESDEN
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - DE
Städtisches Klinikum Dresden
4. Medizinische Klinik - Hämatologie, internistische Onkologie und Palliativmedizin
ALLEMAGNE
Sachsen
LEIPZIG
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - DE
Universitätsklinikum Leipzig AöR
UCCL - Universitäres Krebszentrum Leipzig
ALLEMAGNE
Sachsen-Anhalt
MAGDEBURG
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - DE
Universitätsklinikum Magdeburg A.ö.R
Universitätsklinik für Gastroenterologie, Hepatologie und Infektiologie
AUSTRALIE
Victoria
ADDRESS: NOT PROVIDED - AU
A Phase Ib/II Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma -AU
Institution: Information not provided - AU
AUTRICHE
OBERÖSTERREICH
LINZ
IMpower133: A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer - AT
Kepler Universitätsklinikum - Med Campus III.
Klinik für Lungenheilkunde
AUTRICHE
OBERÖSTERREICH
LINZ
IMmotion010: A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy - AT
Ordensklinikum Linz GmbH Elisabethinen
Abteilung für Urologie und Andrologie
AUTRICHE
SALZBURG
SALZBURG
IMagyn050: A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer - AT
Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
Universitätsklinik für Frauenheilkunde und Geburtshilfe
AUTRICHE
SALZBURG
SALZBURG
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody), in Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - AT
Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
Universitätsklinik für Innere Medizin III
AUTRICHE
SALZBURG
SALZBURG
IMpower133: A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer - AT
Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
Universitätsklinik für Pneumologie/Lungenheilkunde
AUTRICHE
SALZBURG
SALZBURG
IMmotion010: A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy - AT
Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
Universitätsklinik für Urologie und Andrologie
AUTRICHE
STEIERMARK
GRAZ
IMagyn050: A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer - AT
KH Barmherzige Brüder Graz - Standort Graz-Marschallgasse
Abteilung für Gynäkologie
AUTRICHE
TIROL
INNSBRUCK
IMagyn050: A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer - AT
Medizinische Universität Innsbruck
Universitätsklinik für Gynäkologie und Geburtshilfe
AUTRICHE
TIROL
INNSBRUCK
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody), in Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - AT
Medizinische Universität Innsbruck
Universitätsklinik für Innere Medizin V - Hämatologie und Onkologie
AUTRICHE
WIEN
ADDRESS: NOT PROVIDED - AT
ATALANTE: A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab - AT
Institution: Information not provided - AT
AUTRICHE
WIEN
ADDRESS: NOT PROVIDED - AT
AtTEnd: Phase III Double-blind Randomized Placebo Controlled Trial of Atezolizumab in Combination With Paclitaxel and Carboplatin in Women With Advanced/Recurrent Endometrial Cancer - AT
Institution: Information not provided - AT
AUTRICHE
WIEN
ADDRESS: NOT PROVIDED - AT
An Open-Label, Multicohort, Phase II Study of Atezolizumab in Advanced Solid Tumors (Phase 2) - AT
Institution: Information not provided - AT
AUTRICHE
WIEN
ADDRESS: NOT PROVIDED - AT
PARCT: Phase II Trial of Atezolizumab (Anti-PD-L1) in the Treatment of Stage IIb-IV Mycosis Fungoides/Sezary Syndrome Patients Relapsed/Refractory After a Previous Systemic Treatment - AT
Institution: Information not provided - AT
AUTRICHE
WIEN
ADDRESS: NOT PROVIDED - AT
Atezolizumab in combination with Bevacizumab and Chemotherapy versus Bevacizumab and Chemotherapy in recurrent ovarian cancer - a randomized Phase III trial - AT
Institution: Information not provided - AT
AUTRICHE
WIEN
ADDRESS: NOT PROVIDED - AT
IMbrave251: A Phase III, Open-Label, Randomized Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab - AT
Institution: Information not provided - AT
AUTRICHE
WIEN
ADDRESS: NOT PROVIDED - AT
TREASURE: Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease: a Randomized, Open-label, Multicenter Phase II Study - AT
Institution: Information not provided - AT
AUTRICHE
WIEN
ADDRESS: NOT PROVIDED - AT
The ABC-HCC Trial: A Phase IIIb, Randomized, Multicenter, Open-label Trial of Atezolizumab Plus Bevacizumab Versus Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma - AT
Institution: Information not provided - AT
AUTRICHE
WIEN
ADDRESS: NOT PROVIDED - AT
SPACE: Single-Arm Phase II-Study in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) With Poor Performance Status Receiving Atezolizumab-Carboplatin-Etoposide - AT
Institution: Information not provided - AT
AUTRICHE
WIEN
WIEN
IMmotion010: A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Onkologie
AUTRICHE
WIEN
WIEN
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody), in Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Onkologie
AUTRICHE
WIEN
WIEN
IMbrave050: A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab (Anti-PD-L1 Antibody) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Gastroenterologie und Hepatologie
AUTRICHE
WIEN
WIEN
The FAB-HCC Trial: Fecal Microbiota Transplant (FMT) combined with Atezolizumab plus Bevacizumab in Patients with HepatoCellular Carcinoma who failed to respond to prior Immunotherapy - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Gastroenterologie und Hepatologie
AUTRICHE
WIEN
WIEN
IMagyn050: A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer - AT
Allgemeines Krankenhaus der Stadt Wien
Universitätsklinik für Frauenheilkunde
AUTRICHE
WIEN
WIEN
IMpower133: A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer - AT
Krankenhaus Nord - Klinik Floridsdorf
Abteilung für Innere Medizin und Pneumologie
AUTRICHE
WIEN
WIEN
IMpower133: A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer - AT
Sozialmedizinisches Zentrum Baumgartner Höhe / Otto Wagner-Spital
2. Interne Lungenabteilung
AUTRICHE
WIEN
WIEN
An early-phase, multicenter, open-label study of the safety and pharmacokinetics of anti-PD-L1 antibody (MPDL3280A) in pediatric and young adult patients with previously treated solid tumors (phase I-II) - AT
St. Anna Kinderspital
Zentrum für Kinder- und Jugendheilkunde
BELGIQUE
ANTWERPEN
EDEGEM (ANTWERPEN)
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - BE
Antwerp University Hospital - UZA
Department of Medical Oncology
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
ATALANTE : un essai de phase III, randomisé, en double aveugle comparant atezolizumab versus placebo chez des patientes atteintes d'un cancer épithélial de l'ovaire, des trompes ou du péritoine, en rechute tardive et traitées par l'association d'une chimiothérapie à base de platine et de bévacizumab - BE
Institution: Information not provided - BE
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
ANDERLECHT (BRUSSELS)
Une étude multicentrique ouverte de phase Ib/II évaluant l'innocuité, l'efficacité et la pharmacocinétique du mosunetuzumab en association avec le tiragolumab avec ou sans atezolizumab chez des patients atteints d'un lymphome non hodgkinien à cellules B récidivant ou réfractaire - BE
Institut Jules Bordet Instituut
Service d'hématologie - Institut Jules Bordet
BELGIQUE
LIEGE
LIEGE
BEAT-meso: Essai de phase III multicentrique et randomisé comparant l'Atezolizumab combiné au Bevacizumab et une chimiothérapie standard versus le Bevacizumab et une chimiothérapie standard en tant que traitement de première intention du mésothéliome pleural malin avancé - BE
CHU de Liège - Domaine universitaire du Sart Tilman
Pneumologie - Allergologie
BELGIQUE
VLAAMS BRABANT
LEUVEN
IMbrave251: Une étude de phase III, ouverte et randomisée, de l'atezolizumab en combinaison avec le lenvatinib ou le sorafénib par rapport au lenvatinib ou au sorafenib seuls dans le carcinome hépatocellulaire préalablement traité par l'atezolizumab et le bévacizumab - BE
UZ Leuven - Campus Gasthuisberg
Dienst maag-, darm- en leverziekten (gastro-enterologie en hepatologie)
CANADA
Québec
ADDRESS: NOT PROVIDED - CA
A phase III, multicenter, randomized, Double-blind, placebo-controlled study of Atezolizumab (anti pd-l1 antibody) as Adjuvant therapy after definitive local Therapy in patients with high-risk Locally advanced squamous cell Carcinoma of the head and neck-CA
Institution: Information not provided - CA
ESPAGNE
Cataluña
BARCELONA
VENEZO-LUNG: Phase Ib/II Trial of the Combination of Atezolizumab With Dendritic Cell Vaccination as Maintenance Treatment in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) After Induction Treatment -ES
Hospital Universitari Dexeus - Grupo Quirónsalud
Servicio de Oncología médica
ESPAGNE
Cataluña
ESPLUGUES DE LLOBREGAT
An early-phase, multicenter, open-label study of the safety and pharmacokinetics of Anti-PD-L1 Antibody (MPDL3280A) in pediatric and young adult patients with previously treated solid tumors -ES (completed)
Hospital Sant Joan de Déu Barcelona
Servicio de Oncología y Hematología
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
A phase II, randomized study of MPDL3280A administered as monotherapy or in combination with Bevacizumab versus Sunitinib in patients with untreated advanced renal cell carcinoma - ES (terminated)
Institution: Information not provided - ES
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
ATALANTE: A randomized, double-blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab -ES
Institution: Information not provided - ES
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
A phase III, multicenter, randomized, double-blind, placebo-controlled study of atezolizumab (anti-PD-L1 antibody) as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck -ES
Institution: Information not provided - ES
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
PARCT: Phase II Trial of Atezolizumab (Anti-PD-L1) in the Treatment of Stage IIb-IV Mycosis Fungoides/Sezary Syndrome Patients Relapsed/Refractory After a Previous Systemic Treatment -ES (completed)
Institution: Information not provided - ES
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
BEAT-meso: A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma - ES
Institution: Information not provided - ES
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody), in Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma -ES
Institution: Information not provided - ES
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
CONTACT-03: A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment - ES
Institution: Information not provided - ES
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
IMbrave251: A Phase III, Open-Label, Randomized Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab - ES
Institution: Information not provided - ES
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
The ABC-HCC Trial: A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoembolization (TACE) in intermediate-stage Hepatocellular carcinoma -ES
Institution: Information not provided - ES
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
Multicenter, Open-label, Phase Ib/II Trial to Evaluate Safety and Efficacy for the Combination of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Myeloid Leukemia Patients - ES
Institution: Information not provided - ES
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
A phase II study exploring the safety and efficacy of atezolizumab administered in combination with obinutuzumab or rituximab amti-CD20 therapy in patients with relapsed/refractory mantle cell lymphoma, marginal zone lymphoma and Waldenström macroglobulinemia - ES (completed)
Institution: Information not provided - ES
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
IMpower133: A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer -ES (completed)
Institution: Information not provided - ES
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
IMbrave150: A phase III, open-label, randomized study of atezolizumab in combination with bevacizumab compared with sorafenib in patients with untreated locally advanced or metastatic hepatocellular carcinoma -ES (completed)
Institution: Information not provided - ES
ESPAGNE
Madrid
MADRID
2SMALL: Phase I-II Study to Assess the Safety, Tolerability and Efficacy of PM01183 and Atezolizumab in Patients with Advanced Small Cell Lung Cancer that Progressed Following Prior Therapy with Platinum-Based Chemotherapy - ES
Hospital Universitario 12 de Octubre
Servicio de Oncología Médica
FRANCE
AUVERGNE-RHONE-ALPES
LYON
ATHENA: Etude européenne multicentrique de phase II évaluant Atezolizumab et Bevacizumab chez des patients atteints de carcinome épidermoïde récidivant ou métastatique de la tête et du cou .
CLCC Léon Bérard
Centre Léon Bérard
FRANCE
BRETAGNE
RENNES
Étude de phase IB évaluant la sécurité et l'efficacité en intratumoral de l'agoniste du CD40 (Selicrelumab) en combinaison avec l'anti-PD-L1 (Atezolizumab) chez les patients atteints d'un lymphome B en rechute ou réfractaire
CHU de Rennes - Hôpital Pontchaillou
CHU Rennes
FRANCE
GRAND-EST
STRASBOURG
ATALANTE : Essai de phase III, randomisé, en double aveugle comparant atezolizumab versus placebo chez des patientes atteintes d'un cancer épithélial de l'ovaire, des trompes ou du péritoine, en rechute sensible au platine et traitées par l'association d'une chimiothérapie à base de platine et de bévacizumab - FR
CHU de Strasbourg - Hôpital de Hautepierre
Pôle d'Onco-hématologie
FRANCE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A Phase II Study of the Anti-PDL1 Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid to Investigate Safety and Efficacy of This Combination in Recurrent Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal - FR
Institution: Information not provided - FR
FRANCE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
CONTACT-03: A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment -FR
Institution: Information not provided - FR
FRANCE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
TRIPLET : Étude de phase II-III randomisée, en ouvert, évaluant les avantages de l'ajout de l'ipilimumab à l'association d'atezolizumab et de bevacizumab chez les patients atteints de carcinome hépatocellulaire recevant un traitement systémique de première intention. -FR
Institution: Information not provided - FR
FRANCE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
HOLMBRAVE : Étude clinique évaluant la tolérance et l'efficacité d'une radiothérapie sélective intra-artérielle au 166Holmium en association avec l'atezolizumab et le bevacizumab pour le carcinome hépatocellulaire non résécable.
Institution: Information not provided - FR
FRANCE
HAUTS-DE-FRANCE
LILLE
Etude de phase Ib/II évaluant la sécurité et l'efficacité de l'atézolizumab en association avec l'obinutuzumab plus le lénalidomide chez les patients présentant un lymphome folliculaire récidivant ou réfractaire - FR
CHRU de Lille - Hôpital Claude Huriez
Service des Maladies du sang
FRANCE
ILE-DE-FRANCE
PARIS
Essai de phase II évaluant le MPDL3280A (anticorps anti-PDL1) seul ou en association avec bevacizumab, ou sunitinib chez des patients présentant un cancer du rein métastatique non traité préalablement - FR
AP-HP. Centre - Université de Paris - HEGP Hôpital Européen Georges Pompidou
Service d'Oncologie Médicale
FRANCE
OCCITANIE
MONTPELLIER
GATA : Etude de phase II évaluant la combinaison atezolizumab, avec venetoclax et obinutuzumab chez des patients atteints de lymphome en rechute ou réfractaire
CHU de Montpellier - Hôpital Saint-Eloi
Département d'Hématologie clinique
FRANCE
OCCITANIE
MONTPELLIER
Neoadjuvant Atezolizumab and Adjuvant Atezolizumab + Bevacizumab in Combination With Percutaneous Radiofrequency Ablation of Small HCC: a Multicenter Randomized Phase II Trial
ICM - Institut régional du Cancer de Montpellier
Service d'oncologie médicale - Médecine B3
ITALIE
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A phase Ib/II study evaluating the safety and efficacy of MPDL3280A in combination with either obinutuzumab plus bendamustine or obinutuzumab plus CHOP in patients with follicular lymphoma or diffuse large B-cell lymphoma - IT
Institution: Information not provided - IT
ITALIE
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Phase II, Randomized Study of Atezolizumab Administered as Monotherapy or In Combination With Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma - IT
Institution: Information not provided - IT
ITALIE
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Phase IIIB, Single Arm, Multicenter Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista
Institution: Information not provided - IT
JAPON
JAPAN
ADDRESS : NOT PROVIDED - JP
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma - JP
Institution: Information not provided - JP
JAPON
JAPAN
ADDRESS : NOT PROVIDED - JP
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Hepatocellular Carcinoma
Institution: Information not provided - JP
JAPON
JAPAN
ADDRESS : NOT PROVIDED - JP
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab - JP
Institution: Information not provided - JP
JAPON
JAPAN
ADDRESS : NOT PROVIDED - JP
CONTACT-03 A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment - JP
Institution: Information not provided - JP
ROYAUME-UNI
Greater London
ADDRESS: NOT PROVIDED - GB
A Phase Ib/II Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma -GB
Institution: Information not provided - GB
ROYAUME-UNI
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF ATEZOLIZUMAB IN COMBINATION WITH OBINUTUZUMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA - GB
Institution: Information not provided - UK
ROYAUME-UNI
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A Phase II, Randomized Study of Atezolizumab Administered as Monotherapy or In Combination With Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma - GB
Institution: Information not provided - UK
ROYAUME-UNI
Hampshire
SOUTHAMPTON
ARGO A phase II study of atezolizumab with rituximab, gemcitabine and oxaliplatin in patients with relapsed or refractory diffuse large b-cell lymphoma who are not candidates for high-dose therapy GB
Southampton General Hospital
Southampton University Hospitals NHS Trust Headquarters
ROYAUME-UNI
South Glamorgan
CARDIFF
A phase III, multicenter, randomized, Double-blind, placebo-controlled study of Atezolizumab (anti pd-l1 antibody) as Adjuvant therapy after definitive local Therapy in patients with high-risk Locally advanced squamous cell Carcinoma of the head and neck-GB
Velindre hospital
Velindre NHS Trust
SUISSE
Suisse Alémanique
BASEL
A phase III, multicenter, randomized, Double-blind, placebo-controlled study of Atezolizumab (anti pd-l1 antibody) as Adjuvant therapy after definitive local Therapy in patients with high-risk Locally advanced squamous cell Carcinoma of the head and neck-GB
Hoffmann-La Roche
Hoffmann - La Roche Ltd.
SUISSE
Suisse Alémanique
BERN
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - CH
Universitätsspital Inselspital
University Hospital Inselspital
SUISSE
Suisse Alémanique
LUZERN
MOLTO: A Multi-Center, Open Label, Uncontrolled, Phase II Clinical Trial Evaluating the Safety and Efficacy of Venetoclax in Combination With Atezolizumab and Obinutuzumab in Richter Transformation of CLL - CH
Luzerner Kantonsspital
Abteilung für Hämatologie
SUISSE
Suisse Alémanique
ZÜRICH
SAKK 17/18 : Overcoming Resistance to Immunotherapy Combining Gemcitabine With Atezolizumab in Advanced NSCLC and Mesothelioma Progressing Under Immune-checkpoint Inhibitors or Gemcitabine. A Multicenter, Single-arm, Open Label Phase II Trial With Two Cohorts
Universitätsspital Zürich
Klinik für Medizinische Onkologie und Hämatologie
SUISSE
Suisse Alémanique
ZÜRICH
MOLTO: A Multi-Center, Open Label, Uncontrolled, Phase II Clinical Trial Evaluating the Safety and Efficacy of Venetoclax in Combination With Atezolizumab and Obinutuzumab in Richter Transformation of CLL - CH
Universitätsspital Zürich
Klinik für Medizinische Onkologie und Hämatologie
SUISSE
Suisse Alémanique
ZÜRICH
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - CH
Universitätsspital Zürich
Klinik für Onkologie
SUISSE
Suisse Italienne
BELLINZONA
MOLTO: A Multi-Center, Open Label, Uncontrolled, Phase II Clinical Trial Evaluating the Safety and Efficacy of Venetoclax in Combination With Atezolizumab and Obinutuzumab in Richter Transformation of CLL - CH
Istituto di Ricerca in Biomedicina
Istituto oncologico di ricerca (IOR)
SUISSE
Suisse Romande
ADDRESS: NOT PROVIDED - CH